Danaher (DHR) Now Covered by Analysts at UBS Group

Equities researchers at UBS Group began coverage on shares of Danaher (NYSE:DHR) in a report released on Monday, The Fly reports. The brokerage set a “buy” rating on the conglomerate’s stock.

DHR has been the subject of several other reports. Cowen reiterated a “buy” rating and issued a $90.00 target price on shares of Danaher in a research note on Wednesday, October 4th. Morgan Stanley reiterated an “overweight” rating and issued a $95.00 target price (up from $86.00) on shares of Danaher in a research note on Friday, October 6th. Zacks Investment Research upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a research note on Thursday, October 5th. Evercore ISI began coverage on shares of Danaher in a research note on Wednesday, January 3rd. They issued an “outperform” rating for the company. Finally, Credit Suisse Group reiterated a “hold” rating and issued a $99.00 target price on shares of Danaher in a research note on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $95.86.

Danaher (DHR) traded down $0.59 on Monday, hitting $99.97. 2,160,000 shares of the company traded hands, compared to its average volume of 2,270,000. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. Danaher has a 1 year low of $78.97 and a 1 year high of $100.88. The firm has a market cap of $69,540.00, a PE ratio of 29.75, a P/E/G ratio of 2.18 and a beta of 1.03.

In other news, Director Donald J. Ehrlich sold 10,578 shares of the company’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the sale, the director now owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Daniel Raskas sold 37,870 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total transaction of $3,534,407.10. The disclosure for this sale can be found here. Insiders have sold 174,437 shares of company stock valued at $16,166,722 over the last 90 days. 12.20% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. GQG Partners LLC purchased a new stake in shares of Danaher during the second quarter worth $101,000. Zions Bancorporation grew its holdings in shares of Danaher by 118.3% during the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after buying an additional 667 shares in the last quarter. Monetary Management Group Inc. grew its holdings in shares of Danaher by 10.7% during the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after buying an additional 150 shares in the last quarter. Acrospire Investment Management LLC grew its holdings in shares of Danaher by 185.5% during the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after buying an additional 1,100 shares in the last quarter. Finally, Motco grew its holdings in shares of Danaher by 8.8% during the second quarter. Motco now owns 2,011 shares of the conglomerate’s stock worth $170,000 after buying an additional 163 shares in the last quarter. 76.12% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Danaher (DHR) Now Covered by Analysts at UBS Group” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/22/danaher-dhr-now-covered-by-analysts-at-ubs-group.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

The Fly

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply